---
schema_version: "secwatch.filing_event.v1"
accession: "0001746473-22-000025"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:55:41.114275+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics Q2 net loss $29.5M; pro-forma cash $379.8M after $215.7M offering

## Summary
- Net loss of $29.5M in Q2 2022 vs $22.8M in prior-year quarter; R&D expenses $26.3M (up from $19.2M).
- Pro-forma cash, cash equivalents and short-term investments of $379.8M as of June 30, 2022.
- PLN-74809 INTEGRIS-IPF Phase 2a met primary endpoint; dose-dependent effects on FVC and QLF observed.
- FDA Fast Track designation for PLN-74809 in PSC; topline data from INTEGRIS-PSC expected H1 2023.
- Received $4.0M milestone from Novartis collaboration; loan facility with Oxford Finance provides up to $100M.

## SEC filing metadata
- accession: 0001746473-22-000025
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000174647322000025/0001746473-22-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000174647322000025/plrx-20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001746473-22-000025
- JSON: https://secwatch.observer/filing/0001746473-22-000025.json
- Plain text: https://secwatch.observer/filing/0001746473-22-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.